Table 3

Contractile effects of ET-1 and 5-CT in MCA and basilar arteries

Biphasic curve

Sigmoidal curve


N

K+ mean ±

s.e.m

Emax 1(%) ±

s.e.m

Emax 2(%) ± s.e.m

pEC50(1) ±

s.e.m

pEC50(2) ±

s.e.m

Emax (%) ±

s.e.m

pEC50 ±

s.e.m


ET-1 MCA


Sham

6

1.76 ± 0.57

152 ± 11

8.59 ± 0.14


SAH

7

1.95 ± 0.34

28 ± 8a, b

148 ± 5

12.62 ± 0.23a, b

9.35 ± 0.22


SAH+SB386023-b at 0 h

5

2.22 ± 0, 35

133 ± 5

8.87 ± 0, 15


SAH+SB386023-b after 6 h

9

1.81 ± 0, 27

176 ± 6

8.92 ± 0.13


SAH+SB386023-b after 12 h

5

1.45 ± 0.27

27 ± 7a, b

149 ± 17

12.02 ± 0.39a, b

9.13 ± 0.17


ET-1 BA


Sham

6

4.00 ± 0.58

119 ± 9

9.37 ± 0.10


SAH

6

3.70 ± 0.47

34 ± 5a, b

126 ± 8

12.21 ± 0.15a, b

9.67 ± 0.02


SAH+SB386023-b at 0 h

6

3.92 ± 0.45

124 ± 5

9.23 ± 0.16


SAH+SB386023-b after 6 h

6

4.23 ± 0.41

155 ± 10

8.80 ± 0.13


SAH+SB386023-b after 12 h

6

3.75 ± 0.32

29 ± 5

125 ± 5

12.41 ± 0.18

9.75 ± 0.23


5-CT MCA


Sham

6

1.67 ± 0.54

17 ± 6a

42 ± 9a

8.40 ± 0.14

6.08 ± 0.64a


SAH

6

2.35 ± 0.40

35 ± 2a, b

60 ± 3a, b

8.47 ± 0.17

7.11 ± 0.01a, b


SAH+SB386023-b at 0 h

5

2.45 ± 0.25

16 ± 5b

43 ± 8

8.48 ± 0.13

6.39 ± 0.33


SAH+SB386023-b after 6 h

6

1.81 ± 0.27

21 ± 5b

45 ± 17

8.43 ± 0, 11

6.33 ± 0.51


SAH+SB386023-b after 12 h

6

2.09 ± 0.35

50 ± 6

92 ± 9

8.37 ± 0.10

6.47 ± 0.02


5-CT BA


Sham

6

3.90 ± 0.62

18 ± 6a

56 ± 9

8.00 ± 0.11a

6.25 ± 0.15


SAH

8

4.00 ± 0.26

43 ± 6a, b

64 ± 5

8.46 ± 0.21a, b

6.68 ± 0.01


SAH+SB386023-b at 0 h

6

3, 89 ± 0.22

20 ± 4b

47 ± 4

8.09 ± 0.21a

6.12 ± 0.12


SAH+SB386023-b after 6 h

6

4.23 ± 0.41

12 ± 3b

47 ± 9

7.92 ± 0.23b

6.05 ± 0.44


SAH+SB386023-b after 12 h

6

3.75 ± 0.43

38 ± 5b

55 ± 4

8.30 ± 0.19a, b

6.48 ± 0.10


Responses were characterized by Emax values, expressed as percent of 63 mM K+ -induced contraction, and pEC50 values (negative logarithm of the molar concentration that produces half maximum contraction). Values are represented as mean ± s.e.m and n represents number of animal. a = significant difference between SAH and control groups, b = significant difference between SAH and SAH treated with SB386023-b

Ansar et al. BMC Neuroscience 2011 12:107   doi:10.1186/1471-2202-12-107

Open Data